UCB (OTCMKTS:UCBJY) Hits New 1-Year High – Here’s Why

UCB SA (OTCMKTS:UCBJY) shares hit a new 52-week high on Tuesday . The company traded as high as $156.07 and last traded at $155.70, with a volume of 1207 shares trading hands. The stock had previously closed at $152.0250.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a research note on Sunday, October 26th. Zacks Research cut UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, UCB currently has an average rating of “Buy”.

UCB Stock Up 2.0%

The firm has a 50 day moving average price of $142.20 and a 200 day moving average price of $129.75.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.